BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33858677)

  • 1. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
    Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
    Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
    de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
    PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
    Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
    J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
    Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
    Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
    Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study.
    Reijnen C; Gogou E; Visser NCM; Engerud H; Ramjith J; van der Putten LJM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Reques A; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AAM; Matias-Guiu X; Amant F; ; Massuger LFAG; Snijders MPLM; Küsters-Vandevelde HVN; Lucas PJF; Pijnenborg JMA
    PLoS Med; 2020 May; 17(5):e1003111. PubMed ID: 32413043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study.
    Buda A; Restaino S; Di Martino G; De Ponti E; Monterossi G; Dinoi G; Magni S; Quagliozzi L; Dell'Orto F; Ciccarone F; Lamanna M; Scambia G; Landoni F; Fanfani F
    Eur J Surg Oncol; 2018 Oct; 44(10):1562-1567. PubMed ID: 30077521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
    Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
    J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
    Bendifallah S; Ouldamer L; Lavoue V; Canlorbe G; Raimond E; Coutant C; Graesslin O; Touboul C; Collinet P; Daraï E; Ballester M;
    Gynecol Oncol; 2017 Jan; 144(1):107-112. PubMed ID: 27789083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology in early-stage endometrial cancer.
    Daix M; Angeles MA; Migliorelli F; Kakkos A; Martinez Gomez C; Delbecque K; Mery E; Tock S; Gabiache E; Decuypere M; Goffin F; Martinez A; Ferron G; Kridelka F
    J Gynecol Oncol; 2021 Jul; 32(4):e48. PubMed ID: 33908709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer.
    Holub K; Biete A
    BMC Cancer; 2018 Dec; 18(1):1280. PubMed ID: 30577833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
    Kommoss FK; Karnezis AN; Kommoss F; Talhouk A; Taran FA; Staebler A; Gilks CB; Huntsman DG; Krämer B; Brucker SY; McAlpine JN; Kommoss S
    Br J Cancer; 2018 Aug; 119(4):480-486. PubMed ID: 30050154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of recurrence in patients with endometrial cancer: A retrospective study.
    Vizza E; Cutillo G; Bruno V; Sperduti I; Mancini E; Baiocco E; Chiofalo B; Cicchillitti L; Certelli C; Zampa A; Piccione E; Corrado G
    Eur J Surg Oncol; 2020 Sep; 46(9):1697-1702. PubMed ID: 32204935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
    Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
    Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
    Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
    Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
    Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
    Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.
    Zeimet AG; Reimer D; Huszar M; Winterhoff B; Puistola U; Azim SA; Müller-Holzner E; Ben-Arie A; van Kempen LC; Petru E; Jahn S; Geels YP; Massuger LF; Amant F; Polterauer S; Lappi-Blanco E; Bulten J; Meuter A; Tanouye S; Oppelt P; Stroh-Weigert M; Reinthaller A; Mariani A; Hackl W; Netzer M; Schirmer U; Vergote I; Altevogt P; Marth C; Fogel M
    J Natl Cancer Inst; 2013 Aug; 105(15):1142-50. PubMed ID: 23781004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.
    Karnezis AN; Leung S; Magrill J; McConechy MK; Yang W; Chow C; Kobel M; Lee CH; Huntsman DG; Talhouk A; Kommoss F; Gilks CB; McAlpine JN
    J Pathol Clin Res; 2017 Oct; 3(4):279-293. PubMed ID: 29085668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.